Brief: MGC Pharmaceuticals Posts FY Revenue Of A$3.4 Mln
31/08/2023 09:24
Aug 31 (Reuters) - MGC Pharmaceuticals Ltd MXC.AX :
* FY REVENUE A$3.4 MILLION VERSUS A$4.7 MILLION
* FY NET LOSS FROM ORDINARY ACTIVITIES AFTER TAX
ATTRIBUTABLE
A$21.1 MILLION VERSUS LOSS A$17.1 MILLION
Source text for Eikon: ID:nASX5gN8R1
Further company coverage: MXC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Enters Long Term Aquiol Licensing And Supply Agreement
Brief: Argent Biopharma Secures A$11M Financing Facility To Complete Strategic Acquisition
Brief: Argent Is Growing Through M&A Projected Merged Company Value Of $100M In Ac8 Asset Acquisition
Australia's Argent BioPharma set for best day in a year on AusCann deal
Brief: Argent Biopharma To Acquire Core Operating Assets And IP Portfolio Of Auscann Group